Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success?
Immunotherapy in the metastatic setting has drastically altered the landscape of treatment for various types of malignancy, including colorectal cancer. The category of immune checkpoint inhibitors has especially emerged as a class of therapy predicated on a more comprehensive understanding of immun...
Main Authors: | Nuttavut Sumransub, Kornpong Vantanasiri, Ajay Prakash, Emil Lou |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-09-01
|
Series: | Molecular Therapy: Oncolytics |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S237277052100067X |
Similar Items
-
Neoadjuvant immunotherapy for colorectal cancer: Right regimens, right patients, right directions?
by: Jiahao Zhu, et al.
Published: (2023-03-01) -
Colorectal cancer in the elderly patient: the role of neo-adjuvant therapy
by: Dodaro Concetta Anna, et al.
Published: (2019-08-01) -
Lipid metabolism-associated genes serve as potential predictive biomarkers in neoadjuvant chemoradiotherapy combined with immunotherapy in rectal cancer
by: Qiliang Peng, et al.
Published: (2024-01-01) -
Metabolic Signatures: Pioneering the Frontier of Rectal Cancer Diagnosis and Response to Neoadjuvant Treatment with Biomarkers—A Systematic Review
by: Răzvan Alexandru Ciocan, et al.
Published: (2024-02-01) -
Lung Cancer Surgery after Neoadjuvant Immunotherapy
by: Dirk Stefani, et al.
Published: (2021-08-01)